United States Department of Defense — CureCurrent

How to interpret these research links

Connected source records

The exact organization name United States Department of Defense appears in 235 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials235

Recruiting shown42

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

Preventing Health Damaging Behaviors in Male and Female Army RecruitsNCT01234103 · lead sponsor · 2010-09-01

The Diabetes Telemonitoring (DiaTel) StudyNCT00245882 · lead sponsor · 2005-10-01

Evaluation of Vasopressin in the Vessels of Ovarian NeoplasmsNCT00160472 · lead sponsor · 2004-03-01

SPARC - Screening for Lung Cancer With Platelets Via an AI-enabled RNA-based ClassifierNCT07460440 · collaborator · 2026-09-08

Psilocybin to Treat Depression in Spinal Cord InjuryNCT07251491 · collaborator · 2026-08-06

Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMDNCT07694986 · collaborator · 2026-08-01

Tirzepatide in Obesity-Driven Endometrial CancerNCT07065552 · collaborator · 2026-04-27

Pulmonary Rehabilitation in Advanced Lung Cancer SurvivorsNCT07104630 · collaborator · 2026-03-16

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPCNCT07090148 · collaborator · 2026-03-03

Engagement of Veterans With Lung CancerNCT07219251 · collaborator · 2026-02-27

Addressing Health Literacy With a Tailored Survivorship Care PlanNCT06674863 · collaborator · 2025-11-07

Using a mHealth App to Improve Quality-of-Life Outcomes in Black Prostate Cancer SurvivorsNCT06651359 · collaborator · 2025-08-24

Imaging of Solid Tumors Using 18F-TRXNCT06942104 · collaborator · 2025-07-03

7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate CancerNCT06826924 · collaborator · 2025-06-03

Impact of Multimodal Telerehabilitation in Rural Patients With Metastatic Prostate CancerNCT07032584 · collaborator · 2025-05-27

Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic RefluxNCT06746623 · collaborator · 2025-04-11

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate CancerNCT06616597 · collaborator · 2025-02-13

Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability StudyNCT06649955 · collaborator · 2025-02-10

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone MetastasisNCT06374459 · collaborator · 2025-01-30

Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung CancerNCT06427954 · collaborator · 2024-08-06

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) TrialNCT05958342 · collaborator · 2024-06-30

A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk FactorsNCT05963971 · collaborator · 2024-03-19

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6NCT06228482 · collaborator · 2024-01-22

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate CancerNCT06059118 · collaborator · 2023-10-04

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair TherapyNCT05359653 · collaborator · 2023-08-01

Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione LevelsNCT05241262 · collaborator · 2023-07-06

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung CancerNCT05620342 · collaborator · 2023-06-21

Ketogenic Diet vs Mixed Diet in Patients With Heart FailureNCT06081543 · collaborator · 2023-05-19

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung CancerNCT05242965 · collaborator · 2023-03-24

Study to Improve Deployment Related Asthma by Using L-Citrulline SupplementationNCT05259904 · collaborator · 2023-03-08

Predict Severe Traumatic Brain InjuryNCT06966713 · collaborator · 2023-02-20

Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBCNCT05464082 · collaborator · 2023-01-06

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast CancerNCT04348747 · collaborator · 2022-12-19

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung CancerNCT05452005 · collaborator · 2022-09-13

Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate CancerNCT05396872 · collaborator · 2022-05-12

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast CancerNCT04329065 · collaborator · 2022-04-20

3D Ultrasound Breast ImagingNCT04692818 · collaborator · 2021-11-10

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate CancerNCT04946370 · collaborator · 2021-08-12

Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible SmokersNCT04722835 · collaborator · 2021-03-01

Sequential Testosterone and Enzalutamide Prevents Unfavorable ProgressionNCT04363164 · collaborator · 2020-08-19

UPenn Observational Research Repository on Neurodegenerative DiseaseNCT04715399 · collaborator · 2020-05-29

Converting HR+ Breast Cancer Into an Individualized VaccineNCT03804944 · collaborator · 2020-03-17

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)NCT02620852 · collaborator · 2016-08-31

Improving Health Literacy in African-American Prostate Cancer PatientsNCT03322891 · collaborator · 2016-07-21

PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target IdentificationNCT05049837 · collaborator · 2007-04-25

SwallowFIT Study in Parkinson's DiseaseNCT07356414 · collaborator · 2026-11-30

NOT_YET_RECRUITING

A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer BurdenNCT07721259 · collaborator · 2026-09-30

NOT_YET_RECRUITING

Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic TherapiesNCT07745569 · collaborator · 2026-08-31

NOT_YET_RECRUITING

Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTDNCT07643974 · collaborator · 2026-08-01

NOT_YET_RECRUITING

TANDem-2: Closing the Gap to Interventions for TANDNCT06879665 · collaborator · 2025-07-15

ENROLLING_BY_INVITATION

Extended Clinical Follow up and Biospecimen Collection for Patients Enrolled in TAILORx and RxPONDER: A Companion ProtocolNCT06786585 · collaborator · 2025-06-01

NOT_YET_RECRUITING

Confirmatory Trial for Alleviating Fatigue in Multiple SclerosisNCT06441617 · collaborator · 2024-12-05

ENROLLING_BY_INVITATION

CALM: Managing Distress in Malignant Brain CancerNCT06180460 · collaborator · 2023-11-10

Increasing Access to Definitive Treatment for Prostate CancerNCT06034431 · collaborator · 2023-09-01

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)NCT05809752 · collaborator · 2023-08-22

ACTIVE_NOT_RECRUITING

A Closed Loop, Doctor to Patient, Mobile Application for Depression in People With Multiple SclerosisNCT05865405 · collaborator · 2023-08-01

ACTIVE_NOT_RECRUITING

Neurophysiology Biomarkers of Cognitive Impairment Associated With Deep Brain StimulationNCT05933681 · collaborator · 2023-07-06

ACTIVE_NOT_RECRUITING

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast CancerNCT05101564 · collaborator · 2023-03-20

Functional Outcomes From Diets in Multiple SclerosisNCT05327322 · collaborator · 2023-03-20

ACTIVE_NOT_RECRUITING

Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority PopulationsNCT05687188 · collaborator · 2023-02-22

ACTIVE_NOT_RECRUITING

Drugs studied in this sponsor's trials

75 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing United States Department of Defense as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

cyclophosphamide6

placebo6

docetaxel5

enzalutamide5

capecitabine4

paclitaxel4

trastuzumab4

carboplatin3

cyclophosphamide RxCUI 3002 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 6 trials placebo RxCUI 8375 · Lead sponsor in 0 linked trial(s) · 2 currently recruiting 6 trials docetaxel RxCUI 72962 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 5 trials enzalutamide RxCUI 1307298 · Lead sponsor in 0 linked trial(s) · 2 currently recruiting 5 trials capecitabine RxCUI 194000 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 4 trials paclitaxel RxCUI 56946 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 4 trials trastuzumab RxCUI 224905 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 4 trials carboplatin RxCUI 40048 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 3 trials erlotinib RxCUI 337525 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 3 trials fulvestrant RxCUI 282357 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 3 trials pembrolizumab RxCUI 1547545 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 3 trials testosterone cypionate RxCUI 835827 · Lead sponsor in 0 linked trial(s) · 2 currently recruiting 3 trials acetylcysteine RxCUI 197 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 2 trials celecoxib RxCUI 140587 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials degarelix RxCUI 475230 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials gemcitabine hydrochloride RxCUI 236234 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials nivolumab RxCUI 1597876 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 2 trials testosterone enanthate RxCUI 37859 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 2 trials vasopressin (USP) RxCUI 11149 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 2 trials vitamin D RxCUI 11253 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials 2-deoxyglucose RxCUI 1733674 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial abiraterone acetate RxCUI 1100071 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial alpelisib RxCUI 2169285 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial aspirin RxCUI 1191 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

collaborator232

lead sponsor3

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.